Table 5

DHA-paclitaxel pharmacokinetic parametersa

No. of patientstfbKe (h 1)Vc (liter)Vss (liter)Vss (liter/m2)t1/2,α (h)t1/2,β (h)Cl (liter/h)Cl (liter/h/m2)Cmax (μg/ml)(24 h)c(tf)c(inf)
2001250.083.43.41.98.5NA0.280.1598120212021321
4001230.083.13.11.78.2NA0.260.15214238323832741
6606270.043.73.72.015NA0.170.0913335,3385,3388,278
(23–29)(9.2)(24)(24)(21)(8.7)(29)(27)(20)(20)(20)(27)
880226, 260.05, 0.034.3, 5.44.3, 5.42.0, 2.714, 23NA0.22, 0.160.10, 0.083416, 3105549, 62525549, 62528899, 10,889
88032790.033.76.63.314930.0980.050543892918,98519,263
(26–506)(23)(31)(48)(30)(14)(47)(20)(5.5)(5.5)(3.9)(2.1)(1.8)
110094240.033.87.53.5171120.110.05560110,23223,82521,004
(75–577)(13)(35)(64)(49)(17)(56)(30)(24)(24)(24)(30)(26)
All dose levels5.72.8
(64)(49)
  • a Values represent mean (CV%).

  • b tf, time of the final quantifiable sample; NA, not applicable; Ke, elimination rate constant; Vc, central volume of distribution; Vss, volume of distribution at steady state; t1/2α, disposition half-life during the α phase; disposition half-life during the β phase; Cls, systemic clearance; Cmax, maximum plasma concentration; AUC (24 h), area under the concentration-time curve from time 0 to 24 h; AUC (inf), AUC from time 0 to infinity.

  • c AUC (24 h) and AUC (inf) were calculated using noncompartmental analysis; all other pharmacokinetic parameters and AUC (inf) were determined using compartmental analysis.